2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, CHIP, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Genetic Disorders, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, GVHD, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, CLL, LGL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Research, AML, Translational Research, MDS, MPN, CML, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2503 Long-term outcomes of allogeneic hematopoietic stem cell transplantation in patients with TCF::hlf fusion-positive acute lymphoblastic leukemia: A single-center 15-year experience

Yan-Yan An, Jing Long2, Yue Lu, PhD3, Peihua (Peggy) Lu, MD4, Jianping Zhang, MD5, Deyan Liu6, Min Xiong7, Ruijuan Sun8, Ning Zhang9, Ying-Ying Fu10, Yang-Yang Hou11, Yanli Zhao12
1 Hebei Yanda Lu Daopei Hospital, Langfang, China
2 Beijing Lu Daopei Hospital, Beijing, China, Beijing Lu Daopei Institute of Hematology, Beijing, China, Hebei Yanda Lu Daopei Hospital, Langfang, China
3 Hebei Yanda Lu Daopei Hospital, Langfang, China
4 Beijing Lu Daopei Hospital, Beijing, China
5 Hebei Yanda Lu Daopei Hospital, Langfang, China
6 Hebei Yanda Lu Daopei Hospital, Langfang, China
7 Hebei Yanda Lu Daopei Hospital, Langfang, China
8 Hebei Yanda Lu Daopei Hospital, Langfang, China
9 Beijing Lu Daopei Hospital, Beijing, China, Beijing Lu Daopei Institute of Hematology, Beijing, China
10 Hebei Yanda Lu Daopei Hospital, Langfang, China
11 Hebei Yanda Lu Daopei Hospital, Langfang, China
12 Hebei Yanda Lu Daopei Hospital, Langfang, China

Background

TCF::HLF fusion-positive B-cell acute lymphoblastic leukemia (B-ALL) is a rare high-risk subtype, accounting for approximately 1% of B-ALL cases, characterized by chemotherapy resistance and poor outcomes. Optimal therapeutic strategies remain undefined, and the impact of immunotherapy and allo-HSCT on achieving durable disease control and survival remains unclear.

Methods

In this retrospective real-world cohort study, consecutive patients with TCF::HLF fusion-positive B-ALL undergoing allo-HSCT between 2012 and 2026 at Hebei Yanda Lu Daopei Hospital were evaluated. TCF::HLF molecular MRD was assessed by RT-qPCR of bone marrow samples, with positivity defined as transcript levels ≥0.001% normalized to ABL1. The primary objective was to evaluate long-term outcomes after allo-HSCT. overall survival (OS) and leukemia-free survival (LFS) were estimated using Kaplan-Meier analysis, while relapse, non-relapse mortality (NRM), GVHD, and infectious complications were analyzed using competing-risk methods.

Results

A total of 21 patients with TCF::HLF fusion-positive B-ALL were included. The median age was 12 years (range, 4–51), and 12 (57.1%) was female. Before transplantation, 16 patients (76.2%) received CAR-T therapy, 19 (90.5%) achieved molecular MRD negativity, and 3 (14.3%) harbored complex cytogenetic abnormalities. Four patients (19.0%) underwent second allo-HSCT after relapse following the first transplantation. At HSCT, 10 patients (47.6%) were in CR1 and 11 (52.4%) in CR2. Haploidentical transplantation was performed in 16 patients (76.2%), and 20 (95.2%) received TBI-based conditioning. All patients achieved engraftment.

After a median follow-up of 35.3 months, allo-HSCT achieved durable disease control in this high-risk population, with 3-year OS and LFS rates of 64.7%(46.6%-89.9%) and 64.9%(46.9%-90.0%), respectively. Three patients experienced relapse after transplantation, occurring at 6, 8, and 13 months after allo-HSCT. The 3-year cumulative incidence of relapse was 14.6% (3.4%, 33.3%), while 3-year NRM was 20.5% (6.0%, 41.0%). Notably, both patients with pre-transplantation detectable TCF::HLF molecular MRD (0.08% and 0.29%) remained alive and relapse-free beyond 3 years.

Transplant-related complications were manageable, with cumulative incidences of grade II–IV and grade III–IV acute GVHD at day 100 of 28.6% (11.3%, 48.7%) and 9.5% (1.5%, 26.6%), respectively. The 3-year incidence of moderate-to-severe chronic GVHD was 25.4% (8.8%, 46.2%). CMV and EBV DNAemia within 180 days occurred in 33.3% (14.4%, 53.6%) and 19.0% (5.7%, 38.3%) of patients, respectively.

Exploratory subgroup analyses suggested that transplantation history and disease status before HSCT may influence outcomes. Patients undergoing second allo-HSCT after relapse following the first transplantation had inferior survival compared with those receiving first allo-HSCT (3-year OS,25.0% vs 75.3%). Patients transplanted in CR1 showed numerically favorable outcomes compared with those in CR2, with 3-year OS rates of 80.0% and 51.1%, and LFS rates of 80.0% and 52%, respectively. Similarly, patients with complex cytogenetic abnormalities showed inferior survival trends compared with those without complex abnormalities (3-year OS, 33.3% vs 70.3%; LFS, 33.3% vs 70.7%). 

Conclusions

In this single-center cohort of patients with TCF::HLF-positive B-ALL, allo-HSCT was associated with favorable long-term outcomes in a subset of patients with this historically high-risk entity. Our findings suggest that transplantation before relapse or disease progression may be beneficial, although confirmation in larger multicenter studies is needed.

 

Yan-Yan An: No relevant conflicts of interest to declare.